We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
French gene therapy company GenSight has announced its GS010 drug indicated for eye condition Leber Hereditary Optic Neuropathy (LHON) failed to meet the primary endpoint at week 48 of a Phase III trial.....